¡¾ÌáÒªÐÎò¡¿ÌÇÄò²¡ÊÓÍøÄ¤²¡±ä£¨DR£©ÊÇÌÇÄò²¡×î³£¼ûÇÒÑÏÖØµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬Ò²ÊǸ÷ÄêËêÈËȺ£¨°üÀ¨¶ùͯ¡¢ÊÂÇé³ÉÄêÈ˺ÍÍíÄêÈË£©Ö÷ÒªµÄÖÂäԵ¹ÊÔÓÉ1¡£2020Ä꣬ȫÇòÓÐÁè¼Ý1.03ÒÚÈËÊܵ½ÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄÓ°Ï죬Ԥ¼Æµ½2045ÄêÕâÒ»Êý×Ö½«ÉÏÉýµ½1.61ÒÚÈË1¡£ÕâÒ»ÑÓÐø¶àÄêµÄÁÙ´²ðó¼²£¬Õý±»Ò»ÏîÖйúÔ´´Í»ÆÆËùº³¶¯¡£¿ËÈÕ£¬¾ÝϤ97¹ú¼Ê£¨ÒÔϼò³Æ¡°97¹ú¼Ê¡±£©×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©ÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÖØ´óÍ»ÆÆ¡£
¡¾ÌáÒªÐÎò¡¿ÌÇÄò²¡ÊÓÍøÄ¤²¡±ä£¨DR£©ÊÇÌÇÄò²¡×î³£¼ûÇÒÑÏÖØµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬Ò²ÊǸ÷ÄêËêÈËȺ£¨°üÀ¨¶ùͯ¡¢ÊÂÇé³ÉÄêÈ˺ÍÍíÄêÈË£©Ö÷ÒªµÄÖÂäԵ¹ÊÔÓÉ1¡£2020Ä꣬ȫÇòÓÐÁè¼Ý1.03ÒÚÈËÊܵ½ÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄÓ°Ï죬Ԥ¼Æµ½2045ÄêÕâÒ»Êý×Ö½«ÉÏÉýµ½1.61ÒÚÈË1¡£ÕâÒ»ÑÓÐø¶àÄêµÄÁÙ´²ðó¼²£¬Õý±»Ò»ÏîÖйúÔ´´Í»ÆÆËùº³¶¯¡£¿ËÈÕ£¬¾ÝϤ97¹ú¼Ê£¨ÒÔϼò³Æ¡°97¹ú¼Ê¡±£©×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©ÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÖØ´óÍ»ÆÆ¡£
ÌÇÄò²¡ÊÓÍøÄ¤²¡±ä£¨DR£©ÊÇÌÇÄò²¡×î³£¼ûÇÒÑÏÖØµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬Ò²ÊǸ÷ÄêËêÈËȺ£¨°üÀ¨¶ùͯ¡¢ÊÂÇé³ÉÄêÈ˺ÍÍíÄêÈË£©Ö÷ÒªµÄÖÂäԵ¹ÊÔÓÉ1¡£2020Ä꣬ȫÇòÓÐÁè¼Ý1.03ÒÚÈËÊܵ½ÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄÓ°Ï죬Ԥ¼Æµ½2045ÄêÕâÒ»Êý×Ö½«ÉÏÉýµ½1.61ÒÚÈË1¡£ÕâÒ»ÑÓÐø¶àÄêµÄÁÙ´²ðó¼²£¬Õý±»Ò»ÏîÖйúÔ´´Í»ÆÆËùº³¶¯¡£¿ËÈÕ£¬¾ÝϤ97¹ú¼Ê£¨ÒÔϼò³Æ“97¹ú¼Ê”£©×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©ÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÖØ´óÍ»ÆÆ¡£
Ò»¡¢ÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄÖÎÁÆÄæ¾³
ÌÇÄò²¡ÊÓÍøÄ¤²¡±äÊÇÒ»ÖÖÏ£ÍûÐÔÑÛ²¿¼²²¡£¬ºã¾Ã¸ßѪÌǻᵼÖÂÊÓÍøÄ¤Î¢Ñª¹ÜËðÉË£¬Òý·¢ÊÓÍøÄ¤È±ÑªÈ±Ñõ£¬½ø¶øÔö½ø²¡ÀíÐÔÐÂÉúѪ¹ÜÐγɣ¬Ôì³ÉÊÓÍøÄ¤ÔöÖ³ÐÔ²¡±ä2¡£ÏÖÔÚ£¬¿¹VEGFÒ©ÎïºÍ¼¤¹â¹âÄýÊõÊÇÖÎÁÆDRµÄ½ð±ê×¼ÁÆ·¨£¬µ«±£´æÐèҪƵÈÔÑÛÄÚ×¢Éä¡¢²¿·Ö»¼ÕßÓ¦´ð²»¼ÑµÈÎÊÌ⣬ؽÐèÐÂÐÍÖÎÁÆÕ½ÂÔ1¡£
½üÄêÀ´µÄÑо¿·¢Ã÷£¬ºÚƤÖÊËØÏµÍ³£¨Melanocortin System£©ÔÚµ÷ÀíÑ×Ö¢·´Ó¦¡¢Ôö½ø×éÖ¯ÐÞ¸´ºÍά³ÖÄÚÇéÐÎÎȹ̷½ÃæÊ©Õ¹Òªº¦×÷ÓÃ3£¬ÎªDRÖÎÁÆÌṩÁËÐÂ˼Ð÷¡£
¶þ¡¢97¹ú¼ÊMCR»·ëÄ£º
¶ÔÊÓÍøÄ¤½á¹¹±£»¤Ð§¹ûÏÔÖø
97¹ú¼ÊÑз¢µÄMCR»·ëÄÔÚDB/DBÌÇÄò²¡Ð¡ÊóÄ£×ÓÖÐÌåÏÖ³öÏÔÖøµÄÊÓÍøÄ¤±£»¤×÷Óá£

ʵÑéЧ¹ûÏÔʾ£¬DB/DBÄ£×ÓСÊóµÄÄں˲㣨INL£©ºÍÍâºË²ã£¨ONL£©ºñ¶ÈÏÔ×ű䱡£¬ÕâÊÇÌÇÄò²¡ÒýÆðÊÓÍøÄ¤±äÐÔµÄµä·¶ÌØÕ÷¡£¶ø¾ÓÉMCR»·ëÄÖÎÁƺó£¬ÊÓÍøÄ¤½á¹¹»ñµÃÏÔןÄÉÆ£º
1. MCR»·ëĵͼÁÁ¿×éºÍ¸ß¼ÁÁ¿×éÏÔʾ¼ÁÁ¿ÒÀÀµÐÔµÄÊÓÍøÄ¤½á¹¹»Ö¸´£»
2. MCR»·ëĸ߼ÁÁ¿×éµÄONLºñ¶È»Ö¸´¿¿½üÕý³£Ë®Æ½¡£
Èý¡¢¶àÖØ»úÖÆÐͬ×÷ÓÃ
97¹ú¼ÊMCR»·ëĵĽ¹µãÓÅÊÆÔÚÓÚÆä¶à°Ðµã×÷ÓûúÖÆ¡£ËüÄ£ÄâÁËÄÚÔ´ÐÔºÚÆ¤ÖÊËØ£¨Èçα- MSH£©µÄÐÄÀí¹¦Ð§£¬Í¨¹ý¼¤»îÑÛÖÐµÄºÚÆ¤ÖÊËØÊÜÌ壬´ÓÑ×Ö¢¡¢Ñª¹Ü¡¢ÆÁÕϺÍÉñ¾µÈ¶à¸öÒªº¦»·½ÚÐͬʩչ×÷ÓÃ1, 4¡£

ǿЧ¿¹Ñ×ÓëÃâÒßµ÷Àí
ÌÇÄò²¡ÊÓÍøÄ¤²¡±äʵÖÊÉÏÊÇÒ»ÖÖÂýÐԵͶÈÑ×Ö¢ÐÔ¼²²¡¡£Ñо¿Ö¤Êµ£¬¼¤»îMCR£¬ÌØÊâÊÇMC1R£¬Äܹ»ÏÔÖøÒÖÖÆºËÒò×ÓκB£¨NF-κB£©µÈÒªº¦´ÙÑ×ÐźÅͨ·µÄ»î»¯5¡£Õâµ¼Ö¶àÖÖ´ÙÑ×Òò×Ó£¨ÈçTNF-α, IL-1β, IL-6£©ºÍÇ÷»¯Òò×Ó£¨ÈçMIP-1α, MIP-2£©µÄ±í´ïϵ÷4¡£¸üÖ÷ÒªµÄÊÇ£¬MCR¼¤¶¯¼ÁÄÜÓÕµ¼¾ßÓп¹Ñ×¹¦Ð§µÄµ÷ÀíÐÔTϸ°û£¨Treg£©µÄÌìÉú£¬²¢Ôö½ø¿¹Ñ×ϸ°ûÒò×ÓIL-10µÄ±í´ï£¬´Ó¶ø½«ÃâÒß·´Ó¦´ÓÆÆËðÐԵĴÙÑ×״̬תÏò±£»¤ÐԵĿ¹Ñ׺ÍÐÞ¸´×´Ì¬4, 5¡£±ðµÄ£¬ÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÄ£×ÓÖУ¬MCR¼¤¶¯¼Á»¹±»Ö¤Êµ¿ÉÒÔÔö½ø¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1±íÐÍÏò¿¹Ñס¢´ÙÐÞ¸´µÄM2±íÐͼ«»¯£¬ÕâÓÐÖúÓÚÑ×Ö¢µÄÏûÍ˺Í×éÖ¯ÐÞ¸´4¡£
¿¹Ñª¹ÜÌìÉúÓë¼õÇáÉøÂ©
³ýÁËÒÖÖÆÑ×Ö¢£¬MCR¼¤¶¯¼ÁÄܹ»Ö±½Ó×÷ÓÃÓÚѪ¹Üϵͳ¡£Ñо¿Åú×¢£¬¼¤»îMC4R¿ÉÒÔÞ׿¹ÊÓÍøÄ¤Î¢Ñª¹ÜÄÚÆ¤Ï¸°ûµÄ¸ßͨ͸ÐÔ5¡£Í¬Ê±£¬¼¤¶¯MC1RÄÜÏÔÖø½µµÍÊÓÍøÄ¤ÖÐѪ¹ÜÄÚÆ¤Éú³¤Òò×Ó£¨VEGF£©µÄˮƽ£¬ÕâÊÇÇý¶¯²¡ÀíÐÔÐÂÉúѪ¹ÜÐγɺÍѪ¹ÜÉøÂ©µÄÒªº¦Òò×Ó4¡£ÕâÖÖͨ¹ýµ÷ÀíÄÚÔ´ÐÔͨ·À´ÒÖÖÆVEGFµÄÆæÒì»úÖÆ£¬ÓëÏÖÓеĿ¹VEGFÒ©ÎïÐγɻ¥²¹£¬¿ÉÄÜΪ½â¾ö¿¹VEGFÖÎÁÆÄÍÒ©ÐÔÎÊÌâÌṩÐÂÕ½ÂÔ¡£
ÎȹÌѪ-ÊÓÍøÄ¤ÆÁÕÏ
Ѫ-ÊÓÍøÄ¤ÆÁÕÏµÄÆÆËðÊÇÌÇÄò²¡ÊÓÍøÄ¤²¡±äѪ¹ÜÉøÂ©ºÍÊÓÍøÄ¤Ë®Ö׵IJ¡Àí»ù´¡¡£MCR¼¤»î¿ÉÏÔÖøÔöÌíÊÓÍøÄ¤ÖÐϸÃÜÅþÁ¬ÂѰף¨ÈçOccludin£©µÄ±í´ï£¬´Ó¶ø´Ó½á¹¹ÉϼӹÌѪ-ÊÓÍøÄ¤ÆÁÕÏ£¬ïÔÌѪ½¬ÒòËØµÄÉøÂ©4¡£
Ö±½Óϸ°û±£»¤Ó뿹µòÍö
MCRµÄϸ°û±£»¤×÷ÓÃÓâÔ½ÁËѪ¹ÜºÍÑ×֢ϸ°û£¬Ö±½Ó»Ý¼°ÊÓÍøÄ¤Éñ¾Ôª¡£α-MSHÒѱ»Ö¤ÊµÄܹ»Í¨¹ý¼¤»îMC1R¼°ÆäÏÂÓεÄAkt/mTORºÍErk1/2 MAPKÐźÅͨ·£¬±£»¤ÊÓÍøÄ¤É«ËØÉÏÆ¤Ï¸°ûÃâÊÜÑõ»¯Ó¦¼¤ÓÕµ¼µÄµòÍö5¡£ÔÚȱѪ/ÔÙ¹à×¢ËðÉËÄ£×ÓÖУ¬MCR¼¤¶¯¼ÁÏÔʾ³ö¶ÔÊÓÍøÄ¤Éñ¾½Úϸ°ûµÄÏÔÖø±£»¤×÷Óã¬ïÔÌϸ°ûµòÍö£¬Õâ¹ØÓÚ±ÜÃâÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖеÄÉñ¾±äÐÔÖÁ¹ØÖ÷Òª¡£
ËÄ¡¢Ô¶¾°Õ¹Íû
ÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄÖÎÁÆÕý´¦ÔÚÒ»¸öתÐÍÆÚ£¬´Ó¼òµ¥µÄVEGFÒÖÖÆÏò¶à°Ðµã¡¢È«·½Î»±£»¤µÄÆ«ÏòÉú³¤¡£97¹ú¼ÊµÄMCR»·ëÄÒ©ÎïÒÀ¸½ÆäÆæÒìµÄ×÷ÓûúÖÆºÍÁîÈ˹ÄÎèµÄÁÙ´²Ç°Êý¾Ý£¬ÓÐÍû³ÉΪÕâÒ»ÁìÓòµÄÖØ°õ²úÆ·£¬ÎªÈ«ÇòÊýÒÚDR»¼Õß´øÀ´ÐµÄÖÎÁÆÑ¡Ôñ¡£
ÎÄÕÂȪԴÓÚҩʱ´ú¹«ÖÚºÅ
²Î¿¼ÎÄÏ×
1. Seo, H., Park, S. J., & Song, M. (2025). Diabetic Retinopathy (DR): Mechanisms, Current Therapies, and Emerging Strategies. Cells, 14(5), 376. https://doi.org/10.3390/cells14050376
2. áÓÖÝÉòÊÏÑÛ¿ÆÒ½Ôº£¨2024£©. ÌÇÄò²¡ÐÔÊÓÍøÄ¤²¡±ä¿ÆÆÕ. ΢ÐŹ«ÖÚºÅ. Available at:https://mp.weixin.qq.com/s?__biz=MzA5NDI4NTcyNw==&mid=2653585500&idx=1&sn=87cf362b3300a3db891c4c19b8296833&chksm=8a0f495e1bf34e32bdd0e087b3d55b6541aac5cd462a1dacdd8b0a2fc8e71fea61b44b2d1bb7&scene=27 £¨Accessed: September 28, 2025£©
3. Kayne, P. et al. (2025). Activating the Melanocortin System Resolves Inflammation, Reduces VEGF Signaling in Diabetic Retinopathy (DR), and Provides Retinal Ganglion Cell (RGC) Protection. Available at:https://palatin.com/wpcontent/uploads/2025/05/PosterPTN_PL9654_Diabetic_RetinopathyARVO_2025050825.pdf (Accessed: September 28, 2025)
4. Rossi, S., Maisto, R., Gesualdo, C., Trotta, M. C., Ferraraccio, F., Kaneva, M. K., Getting, S. J., Surace, E., Testa, F., Simonelli, F., Grieco, P., Merlino, F., Perretti, M., D'Amico, M., & Di Filippo, C. (2016). Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in ExperimentalDiabeticRetinopathy. Mediatorsofinflammation,2016, 7368389. https://doi.org/10.1155/2016/7368389
5. Wang, S., Kahale, F., Naderi, A., Surico, P. L., Yin, J., Dohlman, T., Chen, Y., & Dana, R. (2024). Therapeutic Effects of Stimulating the Melanocortin Pathway in Regulating Ocular Inflammation and Cell Death.Biomolecules,14(2),169. https://doi.org/10.3390/biom14020169
ɨ¶þάÂëÓÃÊÖ»ú¿´
Ïà¹ØÍÆ¼ö